Why the study?
Mendelian randomization and therapeutic interventions raising HDL-C showed no CVD benefit, making the usefulness of HDL-C unclear, while the relevance of HDL particle characteristics, function, and subclasses to CVD remains controversial.
Design
Review
Authors
Loading...
Challenges HDL-C as a therapeutic target; leaves open whether particle number or function better informs CVD risk.
Key points are not available for this paper at this time.
Pappa et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: